Start the learning journey here
Wanting to learn more about medicine access equity? The He Ako Hiringa website is your gateway to free education, resources, tools and data.
Our latest content
Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020.
This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.
Capture, a new online tool, will help He Ako Hiringa members keep track of what they’re learning online.
Clicking the Capture button at the bottom of each educational piece will create a record of the time taken to read, watch or listen to that content. Members will also be able to record their thoughts and reflections on the content, creating a Capture Record that can then be downloaded and used as a record of learning.
If you are a GP practising in New Zealand and would like to use a data analytics tool that can help you assess your prescribing with respect to type-2 diabetes, and allow you to compare your prescribing behaviour to your peers, then sign up now. To sign up to EPiC, simply click here to begin the two-step sign up process.
Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment?
This case study is particularly relevant to prescribers. It originally appeared in the 3 March 2021 issue of New Zealand Doctor Rata Aotearoa and has been republished with permission.
A new study from the University of Auckland examined ethnic variation in the quality use of medicines between Māori and non-Māori older adult populations. Simon Maude from New Zealand Doctor Rata Aotearoa spoke to the study's lead author Joanna Hikaka and investigated the impact of this research.
Thirsty for knowledge?
Subscribe to our newsletter to remain up to date with all our content and new features.